References
- Aitken, M., Berndt, E. R., Cutler, D., Kleinrock, M., & Maini, L. (2016). Has the era of slow growth for prescription drug spending ended? Health Affairs, 35(9), 1595–1603.10.1377/hlthaff.2015.1636
- Alpern, J. D., Stauffer, W. M., & Kesselheim, A. S. (2014). High-cost generic drugs – implications for patients and policymakers. New England Journal of Medicine, 371(20), 1859–1862.10.1056/NEJMp1408376
- Anderson, R. (2014, November). Pharmaceutical industry gets high on fat profits. BBC Online. Retrieved from http://www.bbc.com/news/
- Bach, P. B. (2015, January). Why drugs cost so much. The New York Times. Retreived from https://www.nytimes.com/
- Baker, D. (2006). The savings from an efficient Medicare prescription drug plan. Center for Economic and Policy Research. Retrieved from http://cepr.net/documents/efficient_medicare_2006_01.pdf
- Barlas, S. (2015). States try to control Medicaid pharmaceutical costs: Numerous, diverse cost pressures force myriad reform efforts. Pharmacy and Therapeutics, 40(4), 260.
- Belfield, C. R., & Levin, H. M. (2007a). The economic losses from high school dropouts in California. Santa Barbara, CA: California Dropout Research Project, University of California. Retrieved from http://cdrpsb.org/download.php?file=policybrief1.pdf
- Belfield, C. R., & Levin, H. M. (2007b). The return on investment for improving California’s high school graduation rate. Santa Barbara, CA: California Dropout Research Project, University of California. Retrieved from http://cdrpsb.org/download.php?file=researchreport2.pdf
- Bloom, H. S., & Unterman, R. (2012). Sustained positive effects on graduation rates produced by New York City’s small public high schools of choice. New York, NY: MDRC. Retrieved from https://www.mdrc.org
- Blume-Kohout, M. E., & Sood, N. (2013). Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development. Journal of Public Economics, 97, 327–336.10.1016/j.jpubeco.2012.10.003
- Bradley, E. H., Elkins, B. R., Herrin, J., & Elbel, B. (2011). Health and social services expenditures: Associations with health outcomes. BMJ Quality & Safety, 20(10), 826–831.10.1136/bmjqs.2010.048363
- Brunello, G., Fort, M., Schneeweis, N., & Winter-Ebmer, R. (2016). The causal effect of education on health: What is the role of health behaviors?”. Health Economics, 25(3), 314–336.10.1002/hec.3141
- Bureau of Labor Statistics. (2016). Consumer price index – All urban consumers – Medical Care (Series CUUR0000SAM). Retrieved June 17, 2016, from http://data.bls.gov/timeseries/CUUR0000SAM?output_view=pct_12mths
- Centers for Medicare and Medicaid Services. (2015a). Medicare drug spending dashboard. Retrieved June 17, 2016, from https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2015-Fact-sheets-items/2015-12-21.html
- Centers for Medicare and Medicaid Services. (2015b). National health expenditure accounts. Retrieved February 24, 2017, from https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/downloads/highlights.pdf
- Conti, G., & Heckman, J. J. (2013). The developmental approach to child and adult health. Pediatrics, 131(Suppl. 2), S133–S141.10.1542/peds.2013-0252d
- Conti, G., Heckman, J., & Urzua, S. (2010). The education-health gradient. The American Economic Review, 100(2), 234–238.10.1257/aer.100.2.234
- The Editorial Board.(2015). No justification for high drug prices. The New York Times. Retrieved from https://www.nytimes.com/
- Fellows, G. K., & Hollis, A. (2013). Funding innovation for treatment for rare diseases: Adopting a cost-based yardstick approach. Orphanet Journal of Rare Diseases, 8(1), 180.10.1186/1750-1172-8-180
- Fossett, J. W., & Burke, C. (2004). Medicaid and state budgets in FY 2004: Why Medicaid is so hard to cut. Albany, NY: The Nelson A. Rockefeller Institute of Government.
- Giaccotto, C., Santerre, R. E., & Vernon, J. A. (2005). Drug prices and research and development investment behavior in the pharmaceutical industry. The Journal of Law & Economics, 48(1), 195–214.10.1086/426882
- Groot, W., & van den Brink, H. M. (2004). The health effects of education: Survey and meta-analysis. Retrieved from https://www.researchgate.net/
- Gubits, D., Shinn, M., Bell, S., Wood, M., Dastrup, S., Solari, C. D., … Abt Associates, Inc. (2015). Family options study: Short-term impacts of housing and services interventions for homeless families. U.S. Department of Housing and Urban Development, Office of Policy Development and Research. Retrieved from https://www.huduser.gov/portal/sites/default/files/pdf/FamilyOptionsStudy_final.pdf
- The Guide to Community Preventive Services. (2013). Promoting health equity through education programs and policies: High school completion programs. Retrieved June 20, 2016, from http://www.thecommunityguide.org/healthequity/education/highschoolcompletion.html
- Haines, A., Kovats, R. S., Campbell-Lendrum, D., & Corvalan, C. (2006). Climate change and human health: Impacts, vulnerability and public health. Public Health, 120(7), 585–596.10.1016/j.puhe.2006.01.002
- Hutton, D., Newman-Casey, P. A., Tavag, M., Zacks, D., & Stein, J. (2014). Switching to less expensive blindness drug could save Medicare Part B $18 billion over a ten-year period. Health Affairs, 33(6), 931–939.10.1377/hlthaff.2013.0832
- Kantarjian, H., & Zwelling, L. (2013). Cancer drug prices and the free-market forces. Cancer, 119(22), 3903–3905.10.1002/cncr.28330
- Kemple, J. J. (2008). Career academies: Long-term impacts on labor market outcomes, educational attainment, and transitions to adulthood. New York, NY: MDRC. Retrieved from https://www.mdrc.org
- Levin, H. M., Belfield, C., Hollands, F., Bowden, A. B., Cheng, H., Shand, R., … Hanisch-Cerda, B. (2012). Cost-effectiveness analysis of interventions that improve high school completion. New York: Center for Benefit-Cost Studies of Education, Teachers College, Columbia University.
- Light, D. W. (2009). Global drug discovery: Europe is ahead. Health Affairs, 28(5), w969–w977.10.1377/hlthaff.28.5.w969
- Light, D. W. (2017). Debunking the pharmaceutical research ‘free rider’ myth: A response to Yu, Helms, and Bach. Health Affairs Blog. Retrieved from https://www.healthaffairs.org/
- Light, D. W., & Kantarjian, H. (2013). Market spiral pricing of cancer drugs. Cancer, 119(22), 3900–3902.10.1002/cncr.28321
- Light, D. W., & Lexchin, J. (2012). Pharmaceutical research and development: What do we get for all that money? BMJ, 345, e4348.10.1136/bmj.e4348
- Maxwell, N. L., & Rubin, V. (2000). High school career academies: A pathway to educational reform in urban school districts?. W. E. Upjohn Institute. Retrieved from http://research.upjohn.org/
- Muennig, P., & Woolf, S. H. (2007). Health and economic benefits of reducing the number of students per classroom in US primary schools”. American Journal of Public Health, 97(11), 2020–2027.10.2105/AJPH.2006.105478
- The Office of the Actuary in the Centers for Medicare & Medicaid Services. (2017). National health expenditure historical and projected. Baltimore, MD: U.S. Department of Health and Human Services.
- Pollack, A. (2016, July). Makers of Humira and Enbrel using new drug patents to delay generic versions. The New York Times. Retrieved from https://www.nytimes.com/
- QuintilesIMS. (n.d.) Total nominal spending on medicines in the U.S. from 2002 to 2016 (in billion U.S. dollars). In Statista – The Statistics Portal. Retrieved June 17, 2016, from https://www.statista.com/statistics/238689/us-total-expenditure-on-medicine/
- Reinhardt, U. E. (2001). Perspectives on the pharmaceutical industry. Health Affairs, 20(5), 136–149.10.1377/hlthaff.20.5.136
- Ross, C. E., & Wu, C. (1995). The links between education and health. American Sociological Review, 60(5), 719–745.10.2307/2096319
- Ruhm, C. J. (2000). Parental leave and child health. Journal of Health Economics, 19(6), 931–960.10.1016/S0167-6296(00)00047-3
- Scobie, J. (2015). Global agewatch index 2015. Age International, HelpAge Global Network. Retrieved from https://www.ageinternational.org.uk/
- Shih, C., Schwartz, J., & Coukell, A. (2016). How would government negotiation of Medicare Part D drug prices work? Health Affairs Blog. Retrieved June 17, 2016, from http://healthaffairs.org/blog/
- Stabile, M., Thomson, S., Allin, S., Boyle, S., Busse, R., Chevreul, K., … Mossialos, E. (2013). Health care cost containment strategies used in four other high-income countries hold lessons for the United States. Health Affairs, 32(4), 643–652.10.1377/hlthaff.2012.1252
- Tanaka, S. (2005). Parental leave and child health across OECD countries. The Economic Journal, 115(501), F7–F28.
- Tanenbaum, S. J. (2017). Can payment reform be social reform? The lure and liabilities of the ‘Triple Aim’. Journal of Health Politics, Policy and Law, 42(1), 53–71.10.1215/03616878-3702770
- Thorpe, K. E. (2005). The rise in health care spending and what to do about it. Health Affairs, 24(6), 1436–1445.10.1377/hlthaff.24.6.1436
- Tran, L. D., Zimmerman, F. J., & Fielding, J. E. (2017). Public health and the economy could be served by reallocating medical expenditures to social programs. SSM – Population Health, 3, 185–191.
- Wilson, S. J., Tanner-Smith, E. E., Lipsey, M. W., Steinka-Fry, K., & Morrison, J. (2011). Dropout prevention and intervention programs: Effects on school completion and dropout among school-aged children and youth. Retrieved April 19, 2016, from http://campbellcollaboration.org/lib/project/158/
- Young, P. L., & Olsen, L. (2010). The healthcare imperative: Lowering costs and improving outcomes. Washington, DC: The National Academies Press, Institute of Medicine.
- Yu, N., Helms, Z., & Bach, P. (2017). R&D costs for pharmaceutical companies do not explain elevated US drug prices. Health Affairs Blog. Retrieved from https://www.healthaffairs.org/